Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
暂无分享,去创建一个
B. Ebert | R. Levine | R. Schneider | E. Chen | A. Mullally | Shannon E Elf | Amy Ko | L. J. Breyfogle | Emily A. Rosen | Luke Poveromo | K. Brumme
[1] T. Golub,et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. , 2014, Blood.
[2] Christian Beisel,et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.
[3] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[4] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[5] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.
[6] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[7] David A. Williams,et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. , 2013, Blood.
[8] O. Bernard,et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. , 2012, Blood.
[9] B. Ebert,et al. Myeloproliferative neoplasm animal models. , 2012, Hematology/oncology clinics of North America.
[10] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[11] B. Ebert,et al. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. , 2012, Blood.
[12] M. Gönen,et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. , 2012, Blood.
[13] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[14] W. Vainchenker,et al. New mutations and pathogenesis of myeloproliferative neoplasms. , 2011, Blood.
[15] O. Abdel-Wahab,et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.
[16] D. Kent,et al. Mouse models of myeloproliferative neoplasms: JAK of all grades , 2011, Disease Models & Mechanisms.
[17] J. Spivak,et al. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. , 2011, Experimental hematology.
[18] Erin F. Simonds,et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.
[19] Michael G. Kharas,et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.
[20] R. Kusec,et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.
[21] A. Tichelli,et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. , 2010, Blood.
[22] O. Abdel-Wahab,et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.
[23] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[24] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.
[25] A. Migliaccio,et al. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis , 2009, Expert review of hematology.
[26] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[27] A. Hall,et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.
[28] E. Vellenga,et al. Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity Levels , 2008, Molecular and Cellular Biology.
[29] David Bryder,et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. , 2007, Cell stem cell.
[30] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[31] Soon-Siong Teo,et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. , 2006, Blood.
[32] P. Campbell,et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.
[33] T. Golub,et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.
[34] Jill P. Mesirov,et al. Comparative gene marker selection suite , 2006, Bioinform..
[35] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[36] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[38] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[39] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[40] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[41] D. Charnock-Jones,et al. vavCre Transgenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages , 2002, Genesis.